Results 61 to 70 of about 63,359 (335)
Blood Advances, 2022 Key Points • The diagnostic IDH mutation status in AML did not significantly influence outcomes following HSCT.• IDH1 R132 and IDH2 R172 positive MRD at HSCT is associated with inferior outcomes.
M. Bill +15 more
semanticscholar +1 more source
Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML
New England Journal of Medicine, 2018 Background Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG‐120) is an oral, targeted, small‐molecule inhibitor of mutant IDH1. Methods We conducted a phase 1
C. Dinardo +39 more
semanticscholar +1 more source
Oncometabolites: tailoring our genes [PDF]
, 2015 Increased glucose metabolism in cancer cells is a phenomenon that has been known for over 90 years, allowing maximal cell growth through faster ATP production and redistribution of carbons towards nucleotide, protein and fatty acid synthesis.
Avril N, Buck AC, Gimm O, Higashi K
core +1 more source
British Journal of Biomedical Science, 2022 Background: There are isolated reports of mutations in genes for isocitrate dehydrogenases (IDH1 and IDH2), but few have been examined in a large number of different malignancies. We aimed to analyze mutational prevalence of these genes in a large series
A. K. Murugan, A. S. Alzahrani
semanticscholar +1 more source
Turkish Journal of Hematology, 2017 We aimed to determine the genotype distribution, allele frequency, and prognostic impact of IDH1/2, TET2, and ASXL1 single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs).
Nur Soyer +7 more
doaj +1 more source
The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
BMC Cancer, 2021 Background Non-invasive diagnosis of IDH1 mutation for gliomas has great clinical significance, and PET has natural advantage to detect metabolism, as IDH mutated gliomas share lower glucose consumption. Methods Clinical data of patients with gliomas and
Feng-Min Liu +9 more
doaj +1 more source
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
bioRxiv, 2022 Acute myeloid leukemias (AML) are comprised of multiple cell types with distinct capabilities to propagate the disease and resist therapy. Approximately 20% of AML patients carry gain- of-function mutations in IDH1 or IDH2 that result in over-production ...
E. Gruber +20 more
semanticscholar +1 more source
NIMG-42LOWER BRAIN NETWORK EFFICIENCY IN IDH1 WILD TYPE (IDH-WT) MALIGNANT ASTROCYTOMA COMPARED TO IDH1 MUTANT (IDH1-M) [PDF]
Neuro-Oncology, 2015 We previously demonstrated that patients with IDH1-WT compared to IDH1-M malignant astrocytoma exhibited worse cognitive function. We hypothesized that this is due to greater lesion momentum that may preclude compensatory brain reorganization. Therefore, in the present study, we examined the structural connectome of patients with IDH1-M and -WT tumors ...
Shelli R. Kesler +4 more
openaire +2 more sources
NRF2 signalling in cytoprotection and metabolism
British Journal of Pharmacology, EarlyView., 2023 The KEAP1‐NRF2 system plays a central role in cytoprotection in defence mechanisms against oxidative stress. The KEAP1‐NRF2 system has been regarded as a sulfur‐utilizing cytoprotective mechanism, because KEAP1 serves as a biosensor for electrophiles by using its reactive thiols and NRF2 is a transcriptional factor regulating genes involved in sulfur ...
Shohei Murakami +4 more
wiley +1 more source
International Journal of General Medicine, 2023 Dody Priambada,1 Muhamad Thohar Arifin,1 Abdi Saputro,1 Azka Muzakka,1 Vega Karlowee,2 Udadi Sadhana,2 Yuriz Bakhtiar,1 Krisna Tsaniadi Prihastomo,1 Ajid Risdianto,1 Happy Kurnia Brotoarianto,1 Erie Andar,1 Zainal Muttaqin1 1Department of Neurosurgery ...
Priambada D +11 more
doaj